Immune cells from your own tumor could fight advanced melanoma
NCT ID NCT07310784
First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This phase 2 trial tests a new treatment called LM103 TILs for people with advanced melanoma that has not responded to at least two prior therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then infused back to attack the cancer. The study will compare this approach to standard care in 92 participants, measuring how long the cancer stays under control and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing Go Broad Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Guangxi Medical University Cancer Hospital
RECRUITINGNanning, Guangxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nanjing Drum Tower Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Guangxi Medical University
RECRUITINGNanning, Guangxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Xi'an Jiaotong University
RECRUITINGXi’an, Shanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Third People's Hospital of Zhengzhou
RECRUITINGZhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.